Overall survival, myelofibrosis-free survival, and leukemia-free survival. Kaplan-Meier estimate of (A) overall survival of CALR-positive, JAK2 V617F-positive, and triple-negative groups, (B) myelofibrosis-free survival and (C) leukemia-free survival of the CALR-positive group and JAK2 V617F-positive group.